Drug intelligence / Profile preview

Diclosante

Development stage: Unknown
Lead developer: Pharma Shimi
Modality: Small Molecules
Administration: Rectal

Overview

Diclosante is a branded generic formulation of diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID) developed and marketed by Pharma Shimi. It is available as a rectal suppository in 50 mg and 100 mg strengths. Diclosante is used for the management of acute and chronic pain, inflammation, and musculoskeletal disorders. It exerts its therapeutic effects by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins.

Brand names: DiclosanteDiclosante 100Diclosante100Diclosante-100Diclosante 50Diclosante50Diclosante-50
Other names: دیکلوسانته

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Diclosante.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diclosante.

Explore the full profile